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Keloid disease (KD) is a fibroproliferative lesion of
unknown etiopathogenesis that possibly targets the
PI3K/Akt/mTOR pathway. We investigated whether
PI3K/Akt/mTOR inhibitor, Palomid 529 (P529), which
targets bothmammalian target of rapamycin complex
1 (mTORC-1) and mTORC-2 signaling, could exert
anti-KD effects in a novel KD organ culture assay and
in keloid fibroblasts (KF). Treatment of KF with P529
significantly (P < 0.05) inhibited cell spreading, at-
tachment, proliferation, migration, and invasive
properties at a low concentration (5 ng/mL) and in-
duced substantial KF apoptosis when compared with
normal dermal fibroblasts. P529 also inhibited hy-
poxia-inducible factor-1 expression and completely
suppressed Akt, GSK3, mTOR, eukaryotic initiation
factor 4E-binding protein 1, and S6 phosphorylation.
P529 significantly (P < 0.05) inhibited proliferating
cell nuclear antigen and cyclin D and caused consid-
erable apoptosis. Compared with rapamycin and
wortmannin, P529 also significantly (P < 0.05) re-
duced keloid-associated phenotypic markers in KF.
P529 caused tissue shrinkage, growth arrest, and
apoptosis in keloid organ cultures and substantially
inhibited angiogenesis. pS6, pAkt-Ser473, and mTOR
phosphorylation were also suppressed in situ. P529
1642reduced cellularity and expression of collagen, fi-
bronectin, and -smooth muscle actin (substantially
more than rapamycin). These pre-clinical in vitro and
ex vivo observations are evidence that the mTOR
pathway is a promising target for future KD therapy
and that the dual PI3K/Akt/mTOR inhibitor P529 de-
serves systematic exploration as a candidate agent for
the future treatment of KD. (Am J Pathol 2012, 181:
1642–1658; http://dx.doi.org/10.1016/j.ajpath.2012.08.006)
The mammalian target of rapamycin (mTOR) is a 289-kDa
serine-threonine kinase that regulates cell mobility, sur-
vival, proliferation, transcription, and protein synthesis1–3
and is a negative regulator of autophagy.4–6 Inhibition of
the mTOR pathway has recently become of major interest
in the control of tumor growth.5,7–9 Keloid scars are be-
nign skin lesions that arise from an abnormal wound
healing process in genetically susceptible individu-
als,10,11 and have a high recurrence rate after sur-
gery.12 Primary fibroblasts isolated from keloids exhibit
some “cancer-like” activities and features,13–15 and in-
vasive keloid growth has been compared to malignant
growth.15,16 However, keloids are not truly malignant neo-
plasms because they never metastasize. In KD, there is
excessive angiogenesis and inflammatory cell infiltra-
tion,13,17–21 and, therefore, the mTOR pathway may be a
plausible target pathway in management of KD.
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plexes: mTORC1 and mTORC2. mTORC1 consists of
regulatory associated protein of mTOR (Raptor),
mLST8 (also known as G-protein -subunit–like pro-
tein, a yeast homolog of LST8), and PRAS40 (proline-
rich Akt substrate of 40 kDa). mTORC2 contains mTOR
and mLST8, but instead of Raptor, mTORC2 contains
rapamycin-insensitive companion of mTOR (Rictor)
and mammalian stress-activated protein kinase-inter-
acting protein-1 (mSin1).6,22–24
One of the well-studied allosteric inhibitors of mTOR is
rapamycin.23,25 mTORC1, the molecular target of rapa-
mycin, phosphorylates downstream proteins S6K (p70S6
kinase) and 4E-BP1 (eukaryotic initiation factor 4E-bind-
ing protein 1), both involved in translation. However,
inhibition of mTORC1 alone by rapalogs could lead to
enhanced activation of the PI3K axis because of the
mTOR-S6K-IRS1 negative feedback loop.26,27 mTORC2
phosphorylates Akt on Ser473, increasing its enzyme activ-
ity up to 10-fold.28–30 Activated Akt regulates cell growth,
proliferation, cell cycle, apoptosis, and glucose metabo-
lism.28–30 Considering the importance of Akt signaling and
the critical role of mTORC2 in Akt activation, mTORC2, has
become an attractive drug target for many cancers.
Aside from its association with cancer,5,30 dysregulation
of the mTOR pathway has been linked to several fibrotic
diseases including KD.31–34 KD is a dermal fibroproliferative
disorder characterized by excess scar tissue deposited at
the site of cutaneous injury.19,34–36 There is excessive de-
position of extracellular matrix (ECM) components such as
collagen, fibronectin, and -smooth muscle actin (-
SMA).19,31 Keloid fibroblasts (KF) possess bioenergetic
properties that resemble those of cancerous cells13 and,
like these cells, exhibit overexpression of cytokines and
growth factors including excessive expression of vascular
endothelial growth factor.17,37 The scar tissue infiltrates
the surrounding healthy tissue, and the recurrence rate
after excision is as great as 80%.38 Therefore, KD is
considered an aggressive quasi-neoplastic skin lesion
of unknown origin.13,39–41 Many methods are available
for treatment of KD; however, they often fail to produce
a satisfactory outcome.42–44
The mTOR pathway regulates collagen I expression
via a PI3K-independent45 pathway in human dermal fi-
broblasts, and the PI3K/Akt/mTOR pathway is responsi-
ble for overproduction of collagen and ECM in
KD.31,32,46,47 Of note, rapamycin also inhibits ECM de-
position.31,45 Hence, the PI3K/Akt/mTOR pathway is a
potential therapeutic target for the future management of
KD.31–35,48 The challenge, therefore, is to generate con-
vincing pre-clinical evidence in support of this novel KD
treatment strategy, ideally using the best pre-clinical KD
research assay that is currently available, ie, KD organ
culture (OC),21 and to identify well-tolerated mTOR inhib-
itors that effectively antagonize KD growth and ECM de-
position in vitro and in situ.
To meet this challenge, we hypothesized that dual
mTORC-1 and mTORC-2 inhibition would provide supe-
rior inhibition of Akt signaling and angiogenesis and
would produce a greater effect on KF and KD vasculature
than does inhibition of mTORC-1 alone. Unlike rapamy-cin, which inhibits only mTORC-1,23,26,49 the novel PI3K/
Akt/mTOR inhibitor Palomid 529 (P529) inhibits both
mTORC-1 and mTORC-2 signaling.24,27,50–53
Therefore, we investigated the following areas in the
present study: whether the baseline cellular levels of mTOR
and p70S6K and their activated forms differ between pri-
mary KF and normal dermal fibroblasts (NF) isolated from
extralesional and normal healthy skin; whether P529
antagonizes KD growth and ECM deposition in vitro
and in situ in a manner that renders this novel dual
mTORC1/2 inhibitor an ideal candidate for clinical test-
ing in the future management of KD; and whether and
how P529 differs in this respect from standard PI3K/
Akt/mTOR inhibitors (rapamycin and wortmannin).
Materials and Methods
Patient Selection and Recruitment
Keloid tissue was harvested during excisional surgery in
patients confirmed to have clinical and pathologic evidence
of KD as described previously19,36,54 (Figure 1A). Included
in the study were 31 patients (16 men and 15 women; age
range, 17–74 years) with KF, including 8 with extralesional
fibroblasts (normal skin adjacent to a keloid lesion), and 11
patients with NF (4 men and 7 women; age range, 23–65
years). Of 31 keloid tissue samples, 11 were used for ex vivo
KD OC study (see Supplemental Figure S1 at http://ajp.
amjpathol.org). Tissue samples were selected carefully from
patients with no previous treatment history. In most of the in
vitro experiments, samples were matched for sex and age
(patient demographic data are given in Supplemental Ta-
bles S1 and S2 at http://ajp.amjpathol.org). Keloid samples
were obtained from individuals of different races/ethnicities,
all of whom had given approval (obtained from the local
hospital, university, and regional NHS Ethics Committee)
before the surgical procedure.
Establishment of KF and NF Cell Cultures
Primary fibroblast cell cultures were established as de-
scribed previously.19,54 In brief, tissue was washed in
PBS (PAA Laboratories, Ltd., Yeovil, Somerset, UK) and
incubated in 10 mg/mL dispase II (Roche Diagnostics,
Ltd., Burgess Hill, West Sussex, UK) for 3 hours at 37°C,
and epidermis and fat were removed. Next, the dermis
was minced and incubated in 10 mg/mL collagenase A
(Roche Diagnostics). The tissue/cell suspension was
passed through a 100-m filter (cell strainer; BD Biosci-
ences, Oxford, UK) to remove any remaining tissue re-
siduals. Cells were then washed once with PBS and
plated in T25 CellBind flasks (Nunc, Life Technologies
Ltd., Wiesbaden, Germany) as passage 0 (p0) cells.
Cells were maintained in DMEM (Dulbecco’s modified
Eagle’s medium). Passage 1 (p1) to passage 4 (p4) cell
cultures were used in the present study.19,54
p70
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Camptothecin Regimen
P529 was provided by Paloma Pharmaceuticals, Inc.
(Boston, Massachusetts). Rapamycin and wortmannin
were purchased from Merck Chemicals, Ltd. (Beeston,
Nottingham, UK) to assess and compare the effect of
P529. The concentration of rapamycin was determined
on the basis of similar studies of primary fibroblasts.31
The following concentrations were compared: P529 (5,
10, 20, and 40 ng/mL), rapamycin (50 and 100 ng/mL),
and wortmannin (5 and 10 ng/mL). Camptothecin (Sigma-
Aldrich Corp., St. Louis, MO) (250 ng/mL) was used as
a positive control for real-time cell analysis (RTCA), cyto-
toxicity assay via detection of lactate dehydrogenase
(LDH), viability/metabolic activity assay via water-soluble
tetrazolium salts-1 (WST-1), and apoptotic assay (see
Supplemental Figure S1 at http://ajp.amjpathol.org).
Label-Free RTCA
To determine the effect of various drug concentrations on
KF compared with NF in vitro, label-free RTCA was used,
as described previously.19,55,56
Cytotoxicity (LDH) and Cell Viability/Metabolic
Activity (WST-1) Assay
LDH and WST-1 (Roche Diagnostics) assays were per-
formed according to the manufacturer’s instructions after
various drug therapies, as indicated above.
High Throughput In-Cell Western Blotting and
Quantification
Primary KF and NF were subjected to various concentra-
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α-acn tions of mTOR drugs, as indicated above, for 24 hours at37°C in 5% CO2. Then, In-Cell Western Blotting (ICWB) was
performed using the similar protocol as described previ-
ously.19,54,55 In brief, KF and NF were grown to 80% to 85%
confluence in T75 flasks. Before inoculating the cells in
96-well plates, the cells were starved in 0.2% serum DMEM
for 24 hours. Cells were trypsinized and counted using
FACS (fluorescence-activated cell sorting), and 10,000
cells were inoculated in each well of the 96-well plates (Dow
Corning, Ltd., Barry, Vale of Glamorgan, UK) in triplicate
and grown in DMEM for up to 7 to 8 hours at 37°C in 5%
CO2. The cells were then treated for 24 hours using various
drugs. Subsequent to this, the cells were fixed in 4% form-
aldehyde for 30 minutes at room temperature. The wells
were washed three times with PBS (200 L/well), permeab-
ilized with PBS/0.1% Triton X-100 (150 L/well, three times
for 5 minutes each), and blocked in Odyssey blocking buf-
fer (LI-COR Biosciences UK, Ltd., Cambridge, UK) (200
L/well) for 2 hours at room temperature. The 96-well plates
were then incubated using various primary antibodies
(Table 1) overnight at 4°C (50 L/well). They were subse-
quently washed three times with PBS/0.1% Tween-20
(150 L/well). Secondary antibody (1:500) in PBS/0.5%
Tween-20 was then added (50 L/well) (Table 2). The
plates were then incubated for 1 hour at room temperature,
and the wells were washed with PBS/0.1% Tween-20 three
times. The plates were covered with aluminum foil and im-
aged on an Odyssey infrared scanner (LI-COR Biosci-
ences) using microplate 2 setting with sensitivity of 7 in the
800-nmwavelength channel. Data were retrieved using Od-
yssey software, which were then exported and analyzed
using Excel software (Microsoft Corp., Redmond, WA).
-Actin was used as loading control.
Measurement of Early Apoptosis via Annexin V
Staining Followed by FACS
Primary KF and NF were treated using various concen-
pho- 
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Figure 1. A: Schematic representation of a keloid tissue sam-
ple and extralesional keloid tissue sample (internal control tis-
sue harvested from the same patient). B: mTOR and p-mTOR
expression pattern in keloid and extralesional tissue samples.
Original magnification200. C: Representative infrared images
from ICWB analysis of total mTOR, p- mTOR, total p70S6K, and
p-p70S6K in primary KF compared with primary extralesional
fibroblasts (ELF) and NF from healthy control subjects. Bar
graph indicates mean fluorescence intensity of ICWB from
three independent experiments. *P  0.02 indicates significant
overexpression in KF compared with ELF and NF. ELF, extra-
lesional fibroblasts; KF, keloid fibroblasts; NF, normal fibro-
blasts.* 
 Phos
KF  
ELF 
NF 
m
id       trations of P529, rapamycin, and wortmannin, as de-
nvers, M
Novel Dual TORC1/2 Inhibitor in KD 1645
AJP November 2012, Vol. 181, No. 5scribed above. Apoptosis was detected using an annexin
V–FITC (fluorescein isothiocyanate)–labeled apoptosis
detection kit (Abcam PLC, Cambridge, UK) as described
previously.55
In Vitro Two-Dimensional Migration Assay
Each well of a 96-well Oris plate (Oris migration assay kit;
Cambridge Bioscience, Ltd., Cambridge, UK) was
coated with 9 g/mL collagen (BD Biosciences) and in-
cubated for 30 to 45 minutes at 37°C in 5% CO2. After
incubation, wells were rinsed with 1X PBS once, and Oris
cell seeding stoppers were inserted according to the
manufacturer’s instructions. Serum-starved KF and NF
were prelabeled with PKH26 (Sigma-Aldrich) according
to the manufacturer’s instructions, and 2.5 104 cells per
well were seeded in triplicate. For each treatment, one
well without a cell-seeding stopper served as the positive
control. The plate was then incubated overnight at 37°C
in 5%CO2. The next day, the cell-seeding stoppers were
removed from the test wells, and cells were washed once
Table 1. Primary Antibodies Used in the Present Study
Antibody Species raised Isotype Cl
S6 ribosomal protein Mouse monoclonal IgG1 54D
pS6 ribosomal protein
(Ser235/236)
Rabbit monoclonal IgG 91B
p70S6K Rabbit monoclonal IgG NA
p-p70S6K Rabbit monoclonal IgG NA
AKT Rabbit NA NA
p-AKT (Thr308) Rabbit monoclonal IgG 244F
p-AKT (Ser473) Rabbit monoclonal IgG D9E
mTOR Rabbit NA NA
p-mTOR (Ser2448) Rabbit NA NA
GSK-3-/ Rabbit monoclonal IgG D75
p-GSK-3-/ (Ser9) Rabbit monoclonal IgG 5B3
p38 MAP kinase Rabbit NA NA
p-p38 MAP kinase
(Thr180/Tyr182)
Rabbit NA NA
PCNA Mouse monoclonal IgG2a PC1
Cyclin D1 Rabbit monoclonal IgG 92G
Anti-HIF-1 Mouse monoclonal IgG1 ESE
Collagen I Mouse monoclonal IgG1 COL
CD34 Mouse monoclonal IgG1 581
CD31 Mouse monoclonal IgG1 1A1
-SMA Mouse monoclonal IgG2a 1A4
Fibronectin Rabbit polyclonal IgG NA
-Actin Mouse monoclonal IgG1 NA
Abcam PLC, Cambridge, UK; CST, Cell Signaling Technology, Inc., Da
NA, not available or not applicable; Sigma-Aldrich Corp., St. Louis, MO.
Table 2. Secondary Antibodies Used in the Present Study
Antibody
Species
raised Iso
Goat anti-mouse-Alexa Fluor-488 Goat IgG, IgM
Donkey anti-mouse IRDye 800CW Donkey IgG
Donkey anti-rabbit IRDye 800CW Donkey IgG
Donkey anti-mouse IRDye 680CW Donkey IgG
Donkey anti-rabbit IRDye 680CW Donkey IgG
Donkey anti-goat IRDye 680CW Donkey IgGInvitrogen Corp., Carlsbad, CA; LI-COR Biosciences UK, Ltd., Cambridge, Uwith PBS 1X (PAA Laboratories). Then 100 L fresh me-
dium was added with or without various drugs, and the
cells were allowed to migrate for 30 hours in the migra-
tion zone created by cell-seeding stoppers. After com-
pletion of the experiment, micrographs were captured
using an inverted IX71 microscope (Olympus Corp., To-
kyo, Japan) at 4 magnification. Migrated cells in the
migration zone were counted from four independent ex-
periments, and the mean number of migrated cells was
plotted on the graphs.
In Vitro Three-Dimensional Invasion Assay
Inhibition of the invasive capacity of primary KF was
tested using an in vitro three-dimensional (3D) invasion
assay (Oris invasion and detection assay kit; Cambridge
Bioscience) as described previously.19 In brief, 96-well
plates were coated with basement membrane extract
(BME) per the manufacturer’s instructions. After BME
coating, Oris cell-seeding stoppers were inserted in each
well. Serum-starved cells, 2.5  104 cells/well, were
In-cell Western
dilution
IHC-
dilution Product code Source
1:1000 1:100 2317 CST
1:1000 1:75 4857 CST
1:500 NA 9202 CST
1:500 NA 9204 CST
1:1000 1:200 9272 CST
1:1000 NA 4056 CST
1:1000 1:50 4060 CST
1:1000 1:100 2972 CST
1:1000 1:100 2971 CST
1:1000 NA 5676 CST
1:1000 1:400 9323 CST
1:1000 1:50 9212 CST
1:1000 NA 9211 CST
1:2000 1:4000 2586 CST
1:1000 1:25 2978 CST
1:500 NA Ab8366 Abcam
1:500 1:200 Ab6308 Abcam
NA 1:100 Ab45524 Abcam
NA 1:50 ncl-cd31-1a10 Leica
1:500 1:250 A5691 Sigma-Aldrich
1:500 1:250 ab2413 Abcam
1:1000 NA Ab8226 Abcam
A; Leica Microsystems (UK), Ltd., Milton Keynes, Buckinghamshire, UK;
Active
against Dilution
Product
code Source
) Mouse 1:250 A10680 Invitrogen
Mouse 1:800 926–32212 LI-COR
Rabbit 1:800 926–32213 LI-COR
Mouse 1:800 926–32222 LI-COR
Rabbit 1:800 926–32223 LI-COR
Goat 1:800 926–32224 LI-CORone
2
2
9
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0
2
E122
-1
0type
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pers were removed, the cells were washed once with 1X
PBS, and 40 L BME was added on top of the cells. The
plates were reincubated at 37°C in 5% CO2 for 45 to 60
minutes to enable polymerization of BME. After BME po-
lymerization, various mTOR drug treatments were given
for 48 hours, and the cells were allowed to invade (in
the presence of mTOR drugs) the 2-mm invasion zone
created by cell-seeding stoppers. After completion of the
experiment, cells were stained with calcein AM. Micro-
graphs were obtained using an inverted IX71 microscope
(Olympus) at 4 magnification. Invaded cells in the in-
vasion zone were counted from four independent exper-
iments, and the mean number of invaded cells were
plotted on graphs.
Actin Reorganization
Serum-starved, low-density (1.5  104 cells/well), pri-
mary KF (passages p1 to p4) were grown on glass cov-
erslips in 24-well plates, were pre-treated with or without
P529, rapamycin, and wortmannin for 8 hours, then
stimulated with or without 10 ng/mL insulin-like growth
factor-1 (IGF-1) (R&D Systems Europe, Ltd., Abingdon,
Oxfordshire, UK) for 3.5 hours. Cells were then fixed in
4% paraformaldehyde buffered solution for 20 minutes at
4°C and permeabilized with 0.1% Triton X-100 in 1 PBS
(PAA Laboratories) for 15 minutes. Cells were stained
with 1 mg/mL TRITC-conjugated phalloidin (Sigma-
Aldrich) for 30 minutes at room temperature. Actin fila-
ments (F-actin) were visualized and photographed using
a BX53 digital microscope (Olympus). The percentage of
cells with lamellipodia formation was determined by ran-
domly counting at least 250 cells under the fluorescence
microscope at 600 magnification.
Ex Vivo Keloid OC Model
For the serum-free long-term OC of keloid tissue, a re-
cently developed KD OC system was used.36 In brief,
4-mm punch biopsy fragments were prepared from ke-
loid tissue. These were embedded in rat tail collagen gel
matrix at the air-liquid interface. Serum-free William’s E
medium, supplemented with 10 g/mL insulin, 10 ng/mL
hydrocortisone, 2 mmol/L L-glutamine, 100 IU/mL penicil-
lin, and 10 g/mL streptomycin,57 was used to maintain
keloid OC up to 4 weeks (for methodologic details, see
Bagabir et al36).
Keloid OC Volume Shrinkage and Epidermal
Shrinkage
Keloid OC shrinkage, epidermal shrinkage, and cellular-
ity after treatment with various mTOR drugs were as-
sessed as described previously.36
Histochemistry
Tissue specimens were fixed in formaldehyde, embed-
ded in paraffin blocks, and sectioned to 4- to 5-m thick-ness. Paraffinized tissue sections (4 to 5 m) collected at
various times (day 0, day 3, week 1, week 2, and week 4)
were deparaffinized and stained using standard H&E
(Surgipath; Leica Microsystems (UK), Ltd., Milton
Keynes, Buckinghamshire, UK). Micrographs were ob-
tained using an upright fluorescence microscope (BX51;
Olympus).19,36,54
Immunohistology
Tissues were immersed in freshly prepared 4% parafor-
maldehyde in 0.02 mol/L phosphate buffer (pH 7.4) over-
night at 4°C, washed in 1  PBS, and embedded in
paraffin. For immunostaining, 4- to 5-m tissue sections
were hydrated and incubated in 3% H2O2 in methanol for
20 minutes, washed in water, and boiled in 1 mmol/L
EDTA (pH 8.0) for 15 to 20 minutes. Sections were
blocked with 3% to 6% normal goat serum (Vector Lab-
oratories, Ltd., Orton Southgate, Peterborough, UK) and
incubated with various primary antibodies (Table 1) at
specific dilutions overnight at 4°C. After two washes with
1 Tris-buffered saline solution, tissue sections were in-
cubated with respective secondary antibodies (Table 2)
for 30 to 45 minutes at room temperature and detected
using an avidin-biotin complex method kit (Vector Labo-
ratories).19,36
Apoptosis Detection in Situ
To evaluate apoptosis caused by the various concentra-
tions of drugs, double immunofluorescence was used.
Terminal dUTP nick-end labeling [Dead-End TUNEL as-
say; Promega (UK), Ltd., Southampton, Hampshire, UK)
was used as a marker for apoptosis, and DAPI was used
to localize the DNA as described previously.36 The mi-
crographs were obtained using an upright fluorescence
microscope (BX51; Olympus) at200 magnification. The
mean number of apoptotic cells was quantified in five
random fields from each stained tissue section.
OC Fluorescence-Associated
Immunohistochemistry
Cell-specific antigen (CD34 expression) was localized on
4- to 5-m paraffin sections using a similar technique as
described previously.36
Statistical Analysis
Each experiment was performed independently at least
three or four times. Data are given as mean  SEM.
Statistical evaluation of the continuous data was per-
formed using one-way analysis of variance, followed by
Dunnett’s t-test for between-group comparisons. Statisti-
cal analyses were performed using commercially avail-
able software (SPSS version 13.0; SPSS, Inc., Chicago,
IL). P  0.05 was considered statistically significant.
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Elevated Levels of Total and Phosphorylated
Forms of mTOR and p70S6K in KF
mTOR regulates metabolic processes and translation
rates in response to intracellular ATP levels, as well as
extracellular signals by phosphorylating two major trans-
lational components: ribosomal p70KDa S6 kinase
(p70S6K) and eIF4E.58,59 mTOR, p70S6K, and their phos-
phorylated forms are up-regulated in KF compared with
NF.31 Hence, we initially investigated whether there was
overexpression of mTOR, p70S6K, and their phosphory-
lated forms in the keloid samples.
Immunoperoxidase staining for total and phosphory-
lated forms of mTOR showed high expression in KD tis-
sue (n  7) compared with extralesional tissue sections
(n  5) (Figure 1B). ICWB analysis and mean total immu-
noreactivity (fluorescence intensity) also exhibited signif-
icant (P  0.02) up-regulation of mTOR, p-mTOR,
p70S6K, and p-p70S6K in KF (n  12) compared with
fibroblasts isolated from extralesional sites (n  8) and
normal skin (n  5) (Figure 1C). There was also notice-
able overexpression of pS6, one of the downstream
targets of the mTOR signaling pathway, in KD com-
pared with normal skin tissue (see Supplemental Fig-
ure S2 at http://ajp.amjpathol.org). However, there was
no statistically significant difference in the expression
of mTOR, p70S6K, and their phosphorylated forms be-
tween primary extralesional fibroblasts and NF (Figure
Figure 2. ICWB analysis of intracellular signaling events in KF induced
increasing concentration of P529 compared with rapamycin and wortmann
A: Representative photographs of ICWB for KF treated with P529, rapamyc
and wortmannin for 24 hours. B: Average immunoreactivity from three ind
pendent ICWB experiments of KF normalized to -actin. *P  0.05, †P  0.0
indicates significant difference compared with vehicle control group (DMSO1C). These analyses demonstrate that mTOR is highly
active in KD lesions compared with extralesional and
normal skin.
Dose-Dependent Effect of P529 on
PI3K/Akt/mTOR signaling in KF
We next investigated the efficacy of P529 on intracellular
PI3K/Akt/mTOR signaling of primary human KF (n  10)
and NF (n  6). This was compared with rapamycin, the
reference mTOR inhibitor, and wortmannin, a specific
inhibitor of PI3K signaling, using ICWB. Results showed a
statistically significant (P  0.02) concentration-depen-
dent decrease in pAkt-S473 in primary KF at 24 hours of
treatment with both P529 and wortmannin, whereas total
Akt levels were unaffected by both compounds. mTORC1
downstream substrates, 4E-PB, and S6 ribosomal protein
were also efficiently (P 0.02) dephosphorylated by both
compounds. Both P529 and wortmannin inhibited neither
phosphorylated mitogen-activated protein kinase nor
pAkt-T308 as potently as pAkt-S473. Furthermore, P529
successfully reduced (P  0.02) phosphorylation of
p-GSK3, a critical downstream element of the PI3kinase/Akt
cell survival pathway, and HIF1- (P  0.02). As ex-
pected, rapamycin (100 ng/mL) reduced pAkt-S473 at
very low levels, compared with both P529 and wortman-
nin (5 ng/mL), at a higher concentration of 100 ng/mL
(Figure 2, A and B). P529 did not cause any significantby
in.
in,
e-
2,
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centration (5 ng/mL) as compared with rapamycin and
wortmannin (see Supplemental Figure S3 at http://
ajp.amjpathol.org). Considered together, these results
demonstrate that, compared with rapamycin, P529 is a
specific and highly potent inhibitor of Akt/mTOR in pri-
mary human KF.
Dose-Dependent Inhibition of p-mTOR in KF
Subsequently, we compared the inhibition potency of
P529 on p-mTOR with rapamycin and wortmannin. In
ICWB, all three compounds showed significantly (P 
0.02) reduced p-mTOR levels (Figure 3, A and B).
However, rapamycin (100 ng/mL) was less effective in
reducing p-mTOR than were P529 and wortmannin (5
ng/mL). Hence, at low concentrations, P529 is a highly
potent p-mTOR inhibitor in KF (n  8). Unlike rapamy-
cin and wortmannin, P529 did not have any inhibitory
effect on p-mTOR in NF (n  5) (see Supplemental
Figure S4 at http://ajp.amjpathol.org) compared with
KF, which suggests that P529 has a greater p-mTOR
inhibitory effect on KF.
Figure 3. Expression pattern of total and p-mTOR in KF at 24 hours after
treatment with P529, rapamycin, and wortmannin. A: In-Cell Western Blot
was performed to assess the immunoreactivity of mTOR and p-mTOR
after various drug treatments. Representative output infrared images of
treated and untreated fibroblasts, stained for protein expression (visible in
red) are shown. B: Bar graphs represent the quantification of mean
protein expression with various treatments from three independent ex-
periments after normalization to loading control -actin. *P  0.05, sig-
nificant difference in the treated group vs the vehicle (DMSO) control
group.Dose-Dependent Inhibition of Cell Spreading,
Attachment, and Cell Proliferation in KF
We investigated whether P529 has any substantial inhib-
itory effect at the cellular level on KF and NF activity. We
used a label-free RTCA system. RTCA results showed
that primary KF (n  10) and NF (n  5) had cell
indices of 3.8 to 4.2 and 3.0 to 3.7, respectively, at
24 hours of cell growth in the absence of any test
compounds. This confirmed that fibroblasts obtained in
KD (Figure 4, A and B) were significantly (P  0.05)
more aggressive in terms of cell spreading, attach-
ment, and proliferation13,17,32,60,61 compared with NF
(Figure 4B; and see Supplemental Figure S5 at http://
ajp.amjpathol.org).
By using the RTCA assay, we also demonstrated that
P529, rapamycin, and wortmannin inhibited cell spread-
ing, attachment, and proliferation in primary KF in a dose-
and time-dependent manner. Compared with rapamycin
and wortmannin, P529 was highly effective even at very
low concentrations (5 ng/mL). A similar dose- and time-
dependent inhibition was also observed in NF, but with
slightly less efficacy than in KF. However, compared with
rapamycin and wortmannin, P529 was more efficient in
inhibiting both primary KF and NF (Figure 4B).
Consequently, we investigated whether P529 had a
sustained effect on KF and NF after drug retrieval. In both
cell types, when P529 was retrieved, the cells were not
able to recover within 30 hours; rather, the average cell
index was further reduced, which suggests that the drug
effect was sustained in this group compared with groups
treated with rapamycin and wortmannin (Figure 4B). These
results suggest that P529 decreased KF and NF activity
more efficiently than did rapamycin and wortmannin.
Increased Dose-Dependent Cytotoxicity and
Cell Viability/Metabolic Activity in KF
To better understand the inhibitory effect of KF and NF
observed in the RTCA assay, we assessed the efficacy of
P529 on cytotoxicity using an LDH assay, and cell viabil-
ity/metabolic activity using a WST-1 assay.
Both membrane disturbance (cytotoxicity) and mito-
chondrial activity (viability/metabolic activity) were stud-
ied using a range of concentrations of P529 (5, 10, 20,
and 40 ng/mL). All three compounds (P529, rapamycin,
and wortmannin) significantly (P  0.05) increased cyto-
toxicity at various concentrations in primary human KF
(n  10) and NF (n  6). However, the P529-treated group
exhibited higher cytotoxicity than did the groups treated
with rapamycin or wortmannin in KF compared with NF
(see Supplemental Figure S6A at http://ajp.amjpathol.
org). When drug treatments were stopped, P529 sus-
tained cytotoxicity significantly (P  0.05) for up to 30
hours compared with the groups treated with rapamycin
or wortmannin. P529 demonstrated significant toxicity in
KF and NF; however, the effect was reversible within 24
hours of drug removal in NF but not in KF, and much
higher dosages were required for the growth-inhibitory
d in trip
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tal Figure S6B at http://ajp.amjpathol.org).
WST-1 analysis demonstrated a significant (P  0.05)
increase in viability/metabolic activity of primary KF com-
pared with NF. These results were in agreement with
those of RTCA. P529 and wortmannin were significantly
(P  0.05) more effective in reducing cell viability/meta-
bolic activity in a dose-dependent manner compared
with the dimethyl sulfoxide (DMSO) control group (see
Supplemental Figure S6C at http://ajp.amjpathol.org).
However, rapamycin also reduced the viability/metabolic
activity of KF at much higher concentrations. Compared
with the groups treated with rapamycin, KF in the groups
treated with P529 or wortmannin sustained cell viability/
metabolic activity inhibition up to 24 to 30 hours after
discontinuation of the drug (see Supplemental Figure
S6D at http://ajp.amjpathol.org). P529 was highly selec-
tive and effective in KF and less effective in NF, com-
pared with both rapamycin and wortmannin. From these
results, it was concluded that P529 caused severe toxic-
ity and substantially inhibited viability/metabolic activity.
Inhibition of KF Proliferation by Down-Regulation
of Cell Cycle
P529 greatly reduced KF and NF proliferation. To further
investigate these findings, expression of the cell cycle
proteins PCNA and cyclin D, were evaluated at the pro-
tein level using ICWB. Significant (P  0.02) concentra-
tion-dependent down-regulation of PCNA and cyclin D
was detected in fibroblasts treated with both P529 and
Wortmannin compared with DMSO. However, at a higher
concentration (100 ng/mL), the rapamycin-treated group
also exhibited a similar level of significant (P  0.02)
reduction in PCNA and cyclin D expression compared
Figure 4. Role of mTOR inhibitors on keloid cell behavior using dyna
microelectronic sensor arrays. A: Effect of P529, rapamycin, and wortmanni
KF and NF. Representative data from five independent experiments performe
group. ‡P  0.05, significant difference in growth of KF versus NF.with the DMSO control group in both KF (n 8) (Figure 5,A and B) and NF (n  5) (see Supplemental Figure S7 at
http://ajp.amjpathol.org). Considered together, these re-
sults show that P529 significantly inhibits primary KF ac-
tivity, at least in part by inhibiting PCNA and cyclin D at
the molecular level.
Dose-Dependent Induction
of Apoptosis in KF
On the basis of these results, we hypothesized that P529
might achieve its inhibitory effect on cell spreading, at-
tachment, and proliferation via apoptosis or cellular ne-
crosis. This hypothesis was assessed via dual-labeled
FACS analysis using annexin V and propidium iodide
labeling (annexin V detects early apoptosis and pro-
pidium iodide identifies cell death and necrosis).55 P529,
rapamycin, and wortmannin all significantly (P  0.05)
and dose dependently increased the percentage of cells
positive for annexin V and propidium iodide, compared
with control. Compared with NF (n  4), P529 caused
more apoptosis in KF (n  8) (Figure 6, A and B; and see
Supplemental Figure S8 at http://ajp.amjpathol.org).
Therefore, P529 strongly promotes apoptosis and necro-
sis in human KF.
Inhibition of Migration and Invasion
Properties of KF
These inhibitory properties of P529 were further probed
under 2D and 3D conditions, using a novel in vitro migra-
tion assay. Treatment with P529, rapamycin, and wort-
mannin significantly (P  0.05) reduced the migration
properties of KF (n  6) in 2D migration compared with
the control DMSO-treated group in a concentration-de-
pendent manner. As expected, P529 was more potent in
real-time monitoring of cell adhesion, spreading, and proliferation on
using real-time cell analysis. B: Quantitative analysis of RTCA cell index of
licate are shown. *P 0.05, †P 0.02, significant difference vs DMSO controlmic and
n on KFinhibiting migration properties of KF than was rapamycin,
Mean im
.05, †P 
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other cancer cells, KF have invasive properties.13,54 As
anticipated, in the 3D invasion model, KF (n  8) was
highly invasive. Both P529 and wortmannin significantly
(P  0.01) reduced the invasive properties of KF at 48
hours after treatment. In addition, rapamycin also showed
significant (P  0.05) inhibition of invasion properties of
KF, but with very low efficacy (Figure 7, C and D). Con-
sidered together, these results suggest that P529 has a
potential anti-migration and anti-invasive property for KF.
Inhibition of IGF-1–Stimulated F-Actin
Reorganization in KF
Rapid reorganization of the actin cytoskeleton, a multi-
step process that includes cell polarization, adhesion,
and de-adhesion, is an early event in cell migration and
invasion.62,63 Therefore, we attempted to understand
whether the P529-induced inhibition of cell migration and
invasion is related to prevention of cell polarization or
protrusion. This was assessed using an IGF-1–stimulated
F-actin reorganization assay.64 The results showed that,
in response to stimulation with IGF-1 (10 ng/mL), the actin
cytoskeleton in KF (n  8) undergoes rapid reorganiza-
tion. P529, rapamycin, and wortmannin did not alter the
pattern of basal F-actin distribution, but reduced IGF-1–
stimulated F-actin reorganization at the leading edge and
lamellipodia formation in KF, compared with the control
group. P529 reduced lamellipodia formation more effec-
tively than did rapamycin and wortmannin (Figure 8, A
and B). Considered together, these results suggest that
P529 significantly inhibits F-actin reorganization, which
could be a potential mechanism for inhibition of cell prolif-
Figure 5. Inhibition of keloid-associated fibrotic markers and cell cycle–re
PCNA, and cyclin D 24 at hours after treatment of KF with various drugs. B:
Western Blotting plotted on the graphs after normalizing to -actin. *P  0eration, migration, and invasion properties of primary KF.Dose-Dependent Down-Regulated Expression
of Fibrosis-Associated Keloid Markers
KD has been associated with a number of molecular
markers, and there is increased expression of several key
cytokine and growth factors including vascular endothe-
lial growth factor, transforming growth factor-, platelet-
derived growth factor, and connective tissue growth fac-
tor. In addition, there is overexpression of a number of
characteristic ECM-associated proteins such as colla-
gen, fibronectin, and -SMA.17,31,33,37,61,65 Therefore,
using ICWB, we compared the effect of P529, rapamycin,
and wortmannin on the expression of KD-associated fi-
brotic markers at the protein level. This demonstrated that
all compounds significantly (P 0.04) and dose-depend-
ently down-regulated collagen I, fibronectin, and -SMA
protein expression (Figure 5, A and B), compared with
controls. Again, compared with rapamycin and wortman-
nin, P529 was more effective at very low concentrations
(5 ng/mL) in the inhibition of these ECM proteins, which
was evident in KF (n  8) (Figure 5, A and B). Compared
with rapamycin and wortmannin, P529 did not show sig-
nificant inhibition of ECM in NF (n 5) (see Supplemental
Figure S7 at http://ajp.amjpathol.org). In the present
study, down-regulation of collagen and fibronectin by
P529 (P  0.001) was highly specific for P529 and
strongly significant compared with rapamycin (P  0.05)
and wortmannin (P  0.01). Because we normalized the
expression levels of collagen and fibronectin to -actin
(internal loading control) in ICWB, our data suggest that
this effect was not related to apoptosis or necrosis.
Overall, in the present study we demonstrated that
P529 significantly inhibited primary KF at very low con-
centrations. Rather, a significant effect of P529 was ob-
genes by P529. A: In-Cell Western Blotting of expression of ECM proteins,
munoreactivity values of KF from three independent experiment of In-Cell
0.02, significant difference in treated group vs DMSO control group.gulatedserved in primary NF only at much higher concentrations.
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tively on cells with active mTOR signaling.
Significant Reduction of Keloid Tissue Volume
by P529
To evaluate the therapeutic potential of P529 in the man-
agement of KD, 4-mm biopsy samples of KD tissue (n 
11) were subjected to various concentrations of P529 in a
serum-free, keloid, long-term OC model.21 P529 and
wortmannin significantly (P  0.05) reduced keloid tissue
volume at week 1 (Figure 9A; and see Supplemental
Figure S9 at http://ajp.amjpathol.org), and weight (Figure
9B) at day 3, compared with the vehicle- and rapamycin-
treated groups. However, rapamycin also decreased
(P  0.05) the mean volume and weight of the keloid OC
after 1 week. These data suggest that P529 induced
rapid shrinkage of keloid volume and weight in an ex vivo
Figure 6. P529 induces apoptosis in KF. Apoptosis was detected with drug
treatment using annexin V staining. A: Annexin V staining for FACS. After 24
hours of treatment with indicated drug concentrations, the cells were har-
vested, and FITC-labeled annexin V was added to a final concentration of 2.5
g/mL. To detect dead cells, propidium iodide (PI) was added at 5 g/mL
concentration. Using flow cytometry, dot plots of annexin V on the y axis
against PI on the x axis were used to differentiate viable cells (negative for
both PI and annexin V), apoptotic cells (annexin V–positive cells but exclud-
ing PI, with PI therefore negative), and late apoptotic or necrotic cells
(double-positive for PI uptake and annexin V staining). Nonstained cells and
untreated cells were used as negative controls. B: Annexin V– and PI-positive
KF after 24 hours of treatment with various drugs as indicated in the bar
graphs at different concentrations. Positive cells were counted from three
independent experiments and plotted on the graph as mean  SEM, *P 
0.05, significant difference vs DMSO control group.model.Reduction of Keloid Tissue Epidermal
Thickness, Cellularity, Inflammation, and
Angiogenesis in Situ
We further delineated the anti-keloid effect of P529 in an
ex vivo model. Histologic and morphometric analyses of
the KD OC (n  11) showed that the thickness of the
epidermis overlying the keloid was significantly (P 
0.01) reduced at week 1 of P529 treatment compared
with rapamycin and wortmannin (Figure 9B). Histologic
analysis revealed that up to day 3, the overall tissue
architecture was well preserved after both wortmannin
and rapamycin treatment. Instead, on day 3, thinning of
the stratum granulosum and papillary dermis was ob-
served in the P529 treatment group (see Supplemental
Figure S10 at http://ajp.amjpathol.org). P529 and wort-
mannin caused severe epidermal damage, with pic-
notic nuclei and dislocation of epidermis from dermis,
at weeks 1 to 4 after treatment (Figure 10A). In con-
trast, the rapamycin-treated group exhibited minimal
tissue damage from day 3 to week 4. Both P529 and
wortmannin suppressed cellularity and inflammation by
20% to 30%, and a noticeable decrease was noted in
the hyalinized collagen bundles at weeks 1 to 4 after
treatment, compared with the DMSO control group
(Figure 10). In contrast, rapamycin caused minimal
changes at day 3 to week 4 when compared with the
P529 treatment group.
Because KD exhibits increased ECM formation and
blood vessel density19,23,47 compared with normal dermis
(see Supplemental Figure S2 at http://ajp.amjpathol.
org), we wondered whether P529 would exert any anti-
angiogenic effects in an ex vivo model of KD. P529
showed a significant reduction in vascular density, as
visualized by CD31 and expression of CD34 immuno-
staining. In addition, CD31 cell density (endothelial
cell marker) (n  8) (Figure 10B) and expression of
CD34 immunoreactivity (n  6) (see Supplemental
Figure S11 at http://ajp.amjpathol.org) were drastically
reduced at week 1 after treatment with both P529 and
wortmannin compared with rapamycin. Thus, P529 ex-
erts strong anti-inflammatory and anti-angiogenic
properties in KD tissue.
P529 Inhibits KD Proliferation and Promotes Its
Apoptosis in Situ
From shrinkage of KD volume and epidermal thickness,
we hypothesized that P529 may inhibit proliferation and
cause apoptosis in the keloid ex vivo model. To address
this, we further analyzed the effect of P529 on prolifera-
tion and induction of apoptosis in keloid OC (n  6) up to
4 weeks. P529 (20 ng/mL) showed marked reduction in
PCNA expression at week 1 compared with vehicle-
treated controls (see Supplemental Figure S12 at http://
ajp.amjpathol.org). Furthermore, P529 significantly (P 
0.05) increased apoptosis at week 1 in keloid OC com-
pared with groups treated with vehicle, rapamycin, and
wortmannin (Figure 11, A and B). After 4 weeks, P529
e of var
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in KD OC.
Early Inhibition of PI3K/Akt/mTOR signaling in
an ex Vivo Keloid Model
We also assessed the inhibitory effect of P529 compared
with rapamycin and wortmannin on intracellular signaling
in an ex vivo model. Keloid OC (n  8) tissue was as-
sessed via immunohistochemistry for expression of
mTOR pathway–related markers after various drug treat-
ments at different times.
In the P529 treatment group, expression of p-Akt-S473,
p-mTOR, and p-S6 were already significantly reduced at
week 1, compared with the rapamycin or wortmannin
treatment groups. In the rapamycin and wortmannin
treatment groups, p-Akt-S473, p-mTOR, and p-S6 (see
Supplemental Figure S13, A–C, respectively, at http://
Figure 7. Effect of P529, rapamycin, and wortmannin drugs on KF migration
response toward 2-mm migration zone created by cell seeding stoppers in the
three independent experiments. B: Number of migrated KF in the migration z
counted on the basis of the 0 hour migration pattern and plotted on the grap
of cells invaded into the invasion zone were counted on the basis of the 0 ho
invasion zone created by cell seeding stoppers in the presence and absenc
experiments. *P  0.05, †P  0.02, significant difference in drug-treated groajp.amjpathol.org) were reduced at week 1 to week 4,compared with the control group. This suggests that the
anti-angiogenic effect of P529 in KD OC could be related
to inhibition of mTOR pathway signaling.
Significant Suppression of Collagen I and
Fibronectin by P529 in an ex Vivo Keloid OC
Model
We evaluated the inhibitory effect of P529 on ECM-re-
lated markers in the keloid OC (n  8) model. As ex-
pected, the immunoreactivity of collagen I was reduced
significantly at weeks 1 to 4 after treatment with P529
compared with rapamycin and wortmannin (Figure 12A).
All three compounds produced a significant reduction in
fibronectin immunoreactivity at week 1 after treatment,
compared with the control group. However, the inhibitory
effect on fibronectin was noticeably higher with P529 than
with rapamycin and wortmannin (Figure 12B). Thus, inhi-
asion properties in in vitro 2D and 3D models, respectively. A: KF migration
e and absence of various drugs. Representative micrographs are shown from
h and without drugs. Number of cells migrated into the migration zone were
umber of invaded KF in the invasion zone with and without drugs. Number
ion pattern and plotted on the graph. D: KF invasive response toward 2-mm
ious drugs. Representative micrographs are shown from three independent
MSO control group.and inv
presenc
one wit
h. C: N
ur invasbition of the PI3K/Akt/mTOR signaling pathway by dual
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AJP November 2012, Vol. 181, No. 5mTORC1 and mTORC2 inhibitor P529 significantly re-
duced the expression of KD-associated fibrotic markers.
Discussion
Up-regulation of mTOR and its downstreammolecules has
been well documented in KD.31–35,48 The present study
confirms this by showing overexpression of total mTOR,
p70S6K, and their phosphorylated forms and provides the
first evidence that p-S6, a key downstream target of mTOR,
is also overexpressed in KD. mTOR inhibitors such as ra-
palogs have been studied in KD previously using in vitro
primary cell culture models.31,33,35Although rapalogs are
efficacious in some tumors, their feedback activation may
limit their clinical usefulness.23,25 The dual mTORC1/2
inhibitor P52924,27,51 exhibits considerably higher an-
ti-KD activity than does the allosteric mTORC1 inhibitor
rapamycin,66 and wortmannin67,68 a specific covalent in-
hibitor of PI3K.
The PI3k/Akt/mTOR pathway has proximal and distal
feedback signaling, and although mTOR is a downstream
effector of Akt, mTORC2 can phosphorylate Akt at a
specific site (Ser473), which then hyperactivates Akt via a
feedback mechanism.69 Rapamycin and its analogs (ra-
palogs) or rapamycin mTOR inhibitors are limited in
that they do not affect mTORC2; consequently, dura-
tion of inhibition was shortened due to feedback acti-
vation of Akt.70
Pharmacologic agents such as LY294002 and wort-
mannin target the P110 catalytic subunit of PI3K.72 Peri-
Figure 8. P529 inhibits IGF-I–induced F-actin reorganization. A: Representa
absence of IGF-I, F-actin was randomly distributed across the cells, as reveale
in dotlike structures at the margins of the cells. However, within 3.5 hours
structures resembling protrusions or lamellipodia-like structures compared
bar  20 m. Micrographs at 600 magnification. B: Percentage of cells w
experiments. *P  0.05, significant difference vs IGF-I group; †P  0.05, sigfosine and PX-866 are lipid-based Akt inhibitors. Tricirib-ine (API-2) is selective for Akt-2 inhibition.71,72 However,
targeting proximal pathway components generally results
in broad inhibition of the downstream signaling cascade
and may augment undesirable effects, whereas P529, a
small-molecule synthetic nonsteroidal compound with a
chemical structure derived from dibenzo[c]-chromen-6-
one, is an allosteric dual mTORC1/2 dissociative inhibitor
that abrogates compensatory feedback loop activation.
The P529 mechanism of action is unique in that it
dissociates the various proteins in the mTORC1/2
complex rather than inhibiting via catalytic competitive
inhibition.27,73
In the present study, P529 and wortmannin attenuated
p-Akt(Ser473), p-mTOR, and ribosomal protein pS6
phosphorylation in vitro and ex vivo. In contrast, rapamy-
cin failed to inhibit pAkt(Ser473), p-mTOR, and pS6 as
potently as did P529. Our P529 findings concur with
those of previous studies that showed inhibition of the
PI3K/Akt/mTOR axis by this drug.27,52 Compared with
rapamycin, inhibition with both P529 and wortmannin pro-
duced a greater reduction in downstream effectors of
mTOR in in vitro and ex vivo models.
Compared with rapamycin, both P529 and wortmannin
demonstrated more effective inhibition of cell attachment,
spreading, and cell proliferation, caused significant tox-
icity, and inhibited viability/metabolic activity. Consistent
with our results, P529 caused significant cell proliferation,
inhibition, and cytotoxicity.27,51 Treatment with rapamy-
cin31 and the green tea extract EGCG (epigallocat-
echin),32,61 a natural PI3K/Akt/mTOR inhibitor,49 also
rographs from three independent experiments performed in triplicate. In the
ining with TRITC-conjugated phalloidin. Some of the F-actin was condensed
lation with IGF-I, more F-actin was condensed at the leading edge within
ntreated control cells. Formation of lamellipodia is shown (arrows). Scale
llipodia formation. Results are given as mean  SEM of four independent
difference vs DMSOIGF-I group.tive mic
d by sta
of stimu
with noshowed significant inhibition of primary KF proliferation
l layers o
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AJP November 2012, Vol. 181, No. 5and migration. P529 sustained a significant inhibitory ef-
fect on primary KF (5 ng/mL) and NF (20 ng/mL) activity,
compared with rapamycin and wortmannin, after discon-
tinuation of the drugs. Primary KF recovered from rapamy-
Figure 9. Shrinkage of keloid organ culture (OC) after various drug treatmen
presence of various concentrations of drugs up to 4 weeks, and the tissue was co
tissue OC at different times are indicated in the bar graph. B: Mean length of al
significant reduction of epidermal thickness in the treated group vs the untreat
Figure 10. Effect of P529 on keloid OCcellularity/inflammation and angioge
H&E staining. Tissue was collected after different drug treatments at variou
protocols. Micrographs were obtained using an Olympus BX21 microscop
reticular dermis. Arrows indicate the dislocation of epidermis from derm
dislocation of epidermis in the treated groups. B: Immunoperoxidase analysis of CD3
Original magnification 100. Arrows shows the staining pattern for CD31 cells incin mode of action within 3 days.31 However, in the
present study, all three drugs, P529, rapamycin, and
wortmannin, had no reversibility effect after discontin-
uation of the drug at up to 30 hours. Thus, it seems that
millimeter keloid tissue explants were maintained in collagen gel matrix in the
t different times, as indicated in the bar graphs. A: Average weights of the keloid
f epidermal shrinkage except stratum corneum, given in micrometers, shows a
ol group.*P  0.05, †P  0.02, significant difference vs vehicle control group.
Morphologic analysis of keloid OC tissue after various drug treatments using
as indicated. H&E staining of tissue sections was performed using standard
00 magnification. E, epidermis; K, keratin layer; PD, papillary dermis; RD,
treatment. Pyknotic nuclei are shown in the blue circle. Arrows indicatets. Four-
llected anesis. A:
s times
e at 2
is after1 endothelial cell marker after various drug treatments in keloid OC model.
the treated and untreated groups.
control
Novel Dual TORC1/2 Inhibitor in KD 1655
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primary KF.
In 2D and 3D culture models, P529 and wortmannin
inhibited migration and invasion properties of KF more
effectively than did rapamycin. This might have been
achieved by suppressing F-actin, PCNA, and cyclin D.
Consistent with our P529 data, recently it has been shown
that mTORC2 controls F-actin reorganization,22,26,28,63
and this F-actin reorganization can be inhibited by dual
inhibitors such as P52924,27 and AZD8055.6,28,30 Activa-
tion of the PI3K/Akt/mTOR pathway is important for cell
survival and cell growth.74 Because inhibition of PI3K/Akt/
mTOR induces apoptosis,24,27,51 we analyzed the effect
of P529 on KD apoptosis. Both, P529 and wortmannin
produced marked apoptosis in vitro and ex vivo. In con-
trast, rapamycin produced minimal apoptosis. Consistent
with our results, P529 significantly increased apoptosis in
Figure 11. Effect of P529 on keloid cell apoptosis in OC model. Four-millim
induces massive apoptosis in keloid OC. TUNEL staining (red nuclei and gree
and dermis junction. Original magnification 200. E, epidermis; PD, pa
TUNEL-positive cells. *P  0.05, †P  0.02, significant difference vs DMSO
groups.
Figure 12. Effect of P529 on collagen and fibronectin biosynthesis in the kel
in keloid OC model. B: Inhibition of fibronectin expression by P529 treatment in ke
PD, papillary dermis; RD, reticular dermis. Arrows, intensity of staining with and wtumor cells.27,51 In addition, P529 was more potent than
wortmannin in inducing apoptosis.
PCNA and cyclin D are downstream molecular mark-
ers that can be used to monitor the biological effects of
mTOR on fibroblasts.31 In the present study, P529
strongly inhibited PCNA in vitro and ex vivo and cyclin
D in vitro. These data indicated specificity of P529 in
KD. Corroborating our findings, Ong et al31 also found
that rapamycin inhibits PCNA and cyclin D in pri-
mary KF.
Both P529 and wortmannin, compared with rapamycin,
demonstrated reduced cellularity, inflammation, and hya-
linized collagen bundles. We further explored the efficacy
of P529 by assessing shrinkage of keloid OC tissue vol-
ume and epidermal thickness. These findings demon-
strated that shrinkage of keloid OC resulted in reduction
of average keloid OC volume and significant shrinkage of
loid OC was treated with various drug concentrations as indicated. A: P529
TUNEL-positive cells). The dotted lines indicate demarcation of epidermis
ermis; RD, reticular dermis. B: Morphometric analysis of percentage of
group. Arrows indicate TUNEL-positive cells in the treated and untreated
model. A: Reduction of collagen I biosynthesis expression by P529 treatmenteter ke
n-yellow
pillary doid OC
loid OC model. Original magnification 200. E, epidermis; K, keratin layer;
ithout treatment.
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and wortmannin at very low concentrations (20 and 10
ng/mL, respectively), compared with rapamycin (100 ng/
mL). This could be achieved by inhibition of PCNA and
significant induction of apoptosis. Consistent with our
results, in other tumors, P529 considerably reduced tu-
mor growth and volume,24,27,51 and treatment with EGCG
reduced KF nodules in vivo.32 Compared with rapamycin,
the effect of both P529 and wortmannin on angiogenesis
showed significant reduction in CD31 cells and expres-
sion of CD34 immunoreactivity. Rapamycin did inhibit
CD31 cells at a much higher concentration (100 ng/mL)
than did P529 and wortmannin at weeks 1 to 4. Support-
ing our findings in keloid OC, P529 reduces CD31 cells
in other tumors.27
Akt is a central element in the PI3K/Akt/mTOR network,
and there is increasing evidence that this pathway has an
important role in KD pathogenesis.31,32,34,35 The role of
PI3K in collagen regulation has been demonstrated in
human dermal fibroblasts.75,76 In addition, multiple
downstream targets of PI3K, including Akt and mTOR,
have been linked to collagen regulation.31,45,46,77 Re-
cently, it was demonstrated that the PI3K/Akt/mTOR axis
may have a pivotal role in fibronectin transcription.31,78
Rapamycin reduced glomerular -SMA overexpres-
sion.79 In addition, rapamycin-treated rats with ligated
bile ducts have lower volume fractions of connective tis-
sue and cells positive for -SMA.80 Collagen, fibronectin,
and -SMA are proteins considered characteristic of the
keloid tissue phenotype.66 Compared with rapamycin,
both P529 and wortmannin more significantly reduced
the keloid-associated fibrotic markers collagen I, fi-
bronectin, and -SMA in our in vitro model, and collagen
I and fibronectin in our ex vivo model. Furthermore, the
overall inhibitory effect on expression levels of colla-
gen, fibronectin, and -SMA were higher with P529
than with rapamycin and wortmannin. In line with our
results, Ong et al31 also found that treatment of mTOR
inhibitor (rapamycin) significantly reduced ECM and
-SMA in primary KF.
P529 is highly effective in KF compared with NF, even
at low concentrations, which suggests that P529 is a
highly selective inhibitor of mTOR. This could be due to a
more active PI3K/Akt/mTOR axis in keloids compared
with normal skin. It is unlikely that complete target inhibi-
tion could be sustained over long periods in patients with
KD because PI3K signaling is critical in the maintenance
of normal tissue, although, it is possible that higher doses
given intermittently and intralesionally might result in a
better therapeutic outcome by producing sustained PI3K/
Akt/mTOR inhibition in KD, while allowing time for normal
tissue recovery. An alternative strategy would be to com-
bine PI3K/Akt/mTOR inhibitors with anti-cancer agents
that target other signaling pathways, which are consid-
ered to be dysregulated in KD.
Clinically adverse events have been associated with
the use of the mTORC1 inhibitor rapamycin and its ana-
logs.73 However, with P529, such toxicities have not been
observed to date in ongoing human phase I trials. P529
showed no toxicity in toxicology studies in dogs and rats.
It is important to note that no in vivo toxicity was observedwhen P529 was administered in dose-ranging studies in
dogs and rabbits.81 However, it remains to be formally
concluded that P529 may not only inhibit keloid growth
but also normal wound healing.27,74,81
In conclusion, the present study provides the first avail-
able functional evidence that the PI3K/Akt/mTOR axis is
an important target in KD treatment in situ. Moreover, we
show that dual inhibition of the PI3K/Akt/mTOR kinases
by P529 can inhibit cell proliferation, migration, cellular
invasion, inflammation, and ECM production; reduce tis-
sue volume (shrinkage) and epidermal thickness; and
induce apoptosis. Thus, this dual mTOR inhibitor de-
serves to be systemically explored as an attractive ther-
apeutic option in the future treatment of KD.
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